Inactive Instrument
Checkmate Pharmaceuticals, Inc. Stock
Stocks
CMPI
US1628181083
Biotechnology & Medical Research
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 12/12/2018 | |
Robert Landry
DFI | Director of Finance/CFO | 62 | 31/05/2022 |
James Wooldridge
CTO | Chief Tech/Sci/R&D Officer | 60 | 01/10/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Nouhad Husseini
BRD | Director/Board Member | - | 31/05/2022 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 5/31/22 A | Issuer sale | Director | 36,778 | 0.1700% | ||
| 5/31/22 A | Issuer sale | Chief Financial Officer | 278,480 | 1.2874% | ||
| 5/31/22 A | Issuer sale | Chief Executive Officer | 279,437 | 1.2919% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +0.38% | - | - | 231M | |
| -0.62% | +0.50% | +33.92% | +60.07% | 64.38B | |
| +0.35% | +3.04% | +12.64% | +83.62% | 56.16B | |
| +0.53% | +2.55% | +13.90% | +104.77% | 54.16B | |
| -2.81% | -3.95% | +22.72% | +48.57% | 45.33B | |
| -0.33% | -3.12% | +17.62% | +117.27% | 42.25B | |
| +0.55% | +1.93% | +229.73% | +928.00% | 40.78B | |
| +3.27% | +47.40% | +110.44% | +94.92% | 33.8B | |
| +1.22% | -1.39% | +13.92% | +46.95% | 32.25B | |
| -1.29% | -1.72% | +21.00% | -6.85% | 23.57B | |
| Average | +0.09% | +4.72% | +52.88% | +164.14% | 43.63B | |
| Weighted average by Cap. | +0.02% | +3.64% | +49.57% | +162.47% |
Employees
31
